CoDa Therapeutics, Inc.
CoDa Therapeutics is a biopharmaceutical company focused on the development and commercialization of a new generation of wound care therapeutics known as “gap junction modulators.”
The company’s Gap Junction Modulation technology targets the cell-to-cell communication that leads, amongst other things, to cell death in the initial phases of wound-healing following an injury.
> All News
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers
San Diego, California, May 25, 2010 – CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers...